Member area login
You don't have or don't remember the password!
Click Here
Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091



BC: Articoli scritti da B. Morrocchi

Gestire il rischio clinico in medicina di laboratorio: un’inaspettata piastrinopenia
Clinical risk management in laboratory medicine: an unexpected thrombocytopenia
<p>It is acknowledged that the risk management strategy is cardinal to maintain safety in health care organisations. Clinical risk assessment and management is a continuous and dynamic process aimed to evaluate risks and to develop appropriate plans to reduce them. Internationally, there is an increasing recognition of the need to collect and analyse data on patient safety incidents to facilitate cultural growth and to develop appropriate solutions. The practice of reporting is commonly used, and several countries have established national reporting systems to facilitate large scale monitoring and analysis of data. This activity provides information on the extent, types and causes of errors, adverse events and near misses, supporting healthcare workers in the activity of reporting errors. This case shows how a non-optimal communication between laboratory and clinicians has caused an adverse advent and which corrective actions have been undertaken.</p>
Biochimica Clinica ; 41(1) e1-e3
Casi Clinici - Case Report
 
Risultati preliminari per la definizione dell’intervallo di riferimento per l’indoxyl solfato (indicano) nelle urine
Preliminary results for the definition of a reference interval for urine indoxyl sulfate (indican).
<p>Introduction: the term &ldquo;gut dysbiosis&rdquo; refers to an alteration in the composition and functions of the microbiota that causes the loss of beneficial microorganisms and species diversity with the potential growth of harmful bacteria. This condition has been related to many pathologies, both intestinals and extraintestinals. One method for evaluating the dysbiosis is the determination of urinary metabolites related to intestinal fermentative processes. Among these different molecules, indoxyl-sulfate (IS) is well studied. In this paper, the IS measurement was performed in a group of subjects in order to establish a reference interval.<br />Methods: the measurement was carried out by HPLC method using a&nbsp; fluorescence detector on early morning urine void. The results were expressed for urine creatinine concentration.<br />Results: in a group of 68 subjects (35 males, 33 females), the mean IS concentration was 22.3 &micro;mol/mmol creatinine with a standard deviation of 6.8 and a range of 8.2-36.6. The reference interval at 95%, calculated with the &ldquo;robust method&rdquo;, was 9.0-36.3 &micro;mol/mmol creatinine. The 90% confidence intervals, calculated with the &ldquo;boostrap method&rdquo;, for the lower and upper limit of the reference interval were 6.8-11.5 and 34.0-38.6 respectively.<br />Conclusion: this study is&nbsp; one of the first contributions to the definition of a reference interval for this metabolite in the first morning urine void.</p>
Biochimica Clinica ; 17(1)
Contributi Scientifici - Scientific Papers